Health Trials

Named Patient Program for Mitomycin for Pyelocalyceal Solution

ConditionsUrothelial Cancer of Renal PelvisUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma UreterUrothelial Carcinoma Ureter RecurrentUrothelial CarcinomaUrothelial Carcinoma Recurrent
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18+
SponsorUroGen Pharma Ltd.

About this trial

This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.

Eligibility criteria

Qualifiers

Patients who are suitable to receive JELMYTO and for whom there is reasonable expectation that JELMYTO may provide clinical benefit based on the medical judgment of their prescribing physician.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Mitomycin for pyelocalyceal solution

Treatment groups

No treatment groups listed

Locations

This trial has no locations

Sponsors and collaborators

UroGen Pharma Ltd.

Lead sponsor

Tanner Pharma Group

Collaborator

Source ClinicalTrials.gov